Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Moleculin Biotech (MBRX) is now available.
Moleculin Biotech, Inc. is set to conduct a corporate update webcast to discuss its move to a Phase 3 pivotal trial for Annamycin in combination with Cytarabine, targeting the treatment of Acute Myeloid Leukemia (AML) in patients who haven’t responded to initial therapy. The webcast is scheduled for August 6, 2024, and aims to share progress and future plans for this promising treatment approach.
For an in-depth examination of MBRX stock, go to TipRanks’ Stock Analysis page.